» Articles » PMID: 27542276

Mesenchymal Stromal Cells (MSCs) and Colorectal Cancer: a Troublesome Twosome for the Anti-tumour Immune Response?

Overview
Journal Oncotarget
Specialty Oncology
Date 2016 Aug 20
PMID 27542276
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

The tumour microenvironment (TME) is an important factor in determining the growth and metastasis of colorectal cancer, and can aid tumours by both establishing an immunosuppressive milieu, allowing the tumour avoid immune clearance, and by hampering the efficacy of various therapeutic regimens. The tumour microenvironment is composed of many cell types including tumour, stromal, endothelial and immune cell populations. It is widely accepted that cells present in the TME acquire distinct functional phenotypes that promote tumorigenesis. One such cell type is the mesenchymal stromal cell (MSC). Evidence suggests that MSCs exert effects in the colorectal tumour microenvironment including the promotion of angiogenesis, invasion and metastasis. MSCs immunomodulatory capacity may represent another largely unexplored central feature of MSCs tumour promoting capacity. There is considerable evidence to suggest that MSCs and their secreted factors can influence the innate and adaptive immune responses. MSC-immune cell interactions can skew the proliferation and functional activity of T-cells, dendritic cells, natural killer cells and macrophages, which could favour tumour growth and enable tumours to evade immune cell clearance. A better understanding of the interactions between the malignant cancer cell and stromal components of the TME is key to the development of more specific and efficacious therapies for colorectal cancer. Here, we review and explore MSC- mediated mechanisms of suppressing anti-tumour immune responses in the colon tumour microenvironment. Elucidation of the precise mechanism of immunomodulation exerted by tumour-educated MSCs is critical to inhibiting immunosuppression and immune evasion established by the TME, thus providing an opportunity for targeted and efficacious immunotherapy for colorectal cancer growth and metastasis.

Citing Articles

The changes of digestive system inflammatory, oxidative stress, and histopathology factors following oral mesenchymal stem cells administration in rats with traumatic brain injury.

Eslami M, Raji-Amirhasani A, Khaksari M, Keshavarzi Z, Rostamzadeh F, Sabet N BMC Neurosci. 2025; 26(1):20.

PMID: 40050727 PMC: 11884162. DOI: 10.1186/s12868-025-00936-w.


Mesenchymal stem cells and their extracellular vesicle therapy for neurological disorders: traumatic brain injury and beyond.

Yarahmadi A, Dorri Giv M, Hosseininejad R, Rezaie A, Mohammadi N, Afkhami H Front Neurol. 2025; 16:1472679.

PMID: 39974358 PMC: 11835705. DOI: 10.3389/fneur.2025.1472679.


Mesenchymal Stem Cells in Cancer Therapy.

Baran Z, Cetinkaya M, Baran Y Adv Exp Med Biol. 2024; 1474():149-177.

PMID: 39470980 DOI: 10.1007/5584_2024_824.


Tumor-associated mesenchymal stromal cells modulate macrophage phagocytosis in stromal-rich colorectal cancer via PD-1 signaling.

Leonard N, Corry S, Reidy E, Egan H, OMalley G, Thompson K iScience. 2024; 27(9):110701.

PMID: 39310770 PMC: 11416555. DOI: 10.1016/j.isci.2024.110701.


The multifaceted role of extracellular vesicles in prostate cancer-a review.

Jain D, Dinakar Y, Kumar H, Jain R, Jain V Cancer Drug Resist. 2023; 6(3):481-498.

PMID: 37842237 PMC: 10571058. DOI: 10.20517/cdr.2023.17.


References
1.
Cirri P, Chiarugi P . Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res. 2011; 1(4):482-97. PMC: 3186047. View

2.
Dwyer R, Potter-Beirne S, Harrington K, Lowery A, Hennessy E, Murphy J . Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res. 2007; 13(17):5020-7. DOI: 10.1158/1078-0432.CCR-07-0731. View

3.
Alge D, Zhou D, Adams L, Wyss B, Shadday M, Woods E . Donor-matched comparison of dental pulp stem cells and bone marrow-derived mesenchymal stem cells in a rat model. J Tissue Eng Regen Med. 2009; 4(1):73-81. PMC: 2830796. DOI: 10.1002/term.220. View

4.
Malygin A, Meri S, Timonen T . Regulation of natural killer cell activity by transforming growth factor-beta and prostaglandin E2. Scand J Immunol. 1993; 37(1):71-6. DOI: 10.1111/j.1365-3083.1993.tb01667.x. View

5.
Ryan A, Colleran A, OGorman A, OFlynn L, Pindjacova J, Lohan P . Targeting colon cancer cell NF-κB promotes an anti-tumour M1-like macrophage phenotype and inhibits peritoneal metastasis. Oncogene. 2014; 34(12):1563-74. DOI: 10.1038/onc.2014.86. View